ASRS 2024: Real-world safety and efficacy of aflibercept 8 mg in the treatment of nAMD
July 20th 2024Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
ASRS 2024: Neurotech Pharmaceuticals update on the NT-501 device
July 19th 2024Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals Encapsulated Cell Therapy platform for the potential treatment of Macular Telangiectasia Type 2, with a projected PDUFA goal date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
ASRS 2024: Illuminating subclinical sickle cell activities using dynamic OCT angiography
July 19th 2024Richard B. Rosen, MD, from the New York Eye and Ear Infirmary of Mount Sinai discussed his presentation on sickle cell retinopathy and the measurement with dynamic OCT angiography and quad-fusion adaptive optics imaging at the annual ASRS meeting in Stockholm, Sweden.
ASRS 2024: Diabetic retinopathy lesion types and distribution on ultra-widefield imaging
July 19th 2024Paolo Antonio Silva, MD, discusses his presentation on diabetic retinopathy lesion types and distribution on ultra-widefield imaging and the risk for disease worsening over time at the American Society of Retina Specialists meeting held in Stockholm, Sweden.
ASRS 2024: IOP outcomes following suprachoroidal triamcinolone acetonide in patients with glaucoma
July 19th 2024Danny A. Mammo, MD, sat down with Sydney Crago, Assistant Managing Editor of Modern Retina, to discuss his presentation on intraocular pressure outcomes following suprachoroidal triamcinolone acetonide in patients with glaucoma at the American Society of Retina Specialists meeting held in Stockholm, Sweden.
ASRS 2024: New data for Susvimo demonstrates sustained efficacy in DME, DR
July 18th 2024The 2-year Phase III data presented at the American Society of Retina Specialists 2024 in Stockholm, Sweden, show Susvimo’s potential as an alternative to eye injections to treat diabetic macular edema and diabetic retinopathy.
ASRS 2024: Results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA
July 18th 2024Rishi P. Singh, MD, sat down with Sydney Crago, Editor of Modern Retina, to discuss his presentation on the results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA at the American Society of Retina Specialists meeting held in Stockholm, Sweden.
ASRS 2024: Fas inhibition with ONL1204 for the treatment of geographic atrophy
July 18th 2024Durga Borkar, MD, sat down with Sydney Crago, Assistant Managing Editor of Modern Retina, to discuss her presentation on Fas inhibition with ONL1204 for the Treatment of Geographic Atrophy and the first-time results From a Phase 1b study at the American Society of Retina Specialists meeting held in Stockholm, Sweden.
Welcome to the metaverse: Technology allows ophthalmologists to mingle with colleagues worldwide
July 18th 2024Answers to common questions that can help kick-start the journey into the metaverse to learn from the many virtual educational meetings and conference opportunities while mingling with colleagues worldwide.
ASRS 2024: 72-Week results from phase 3 BALATON and COMINO trials
July 18th 2024Carl Danzig, MD, sat down with Sydney Crago, Assistant Managing Editor of Modern Retina, to discuss his presentation on the 72-Week results from the Phase 3 BALATON and COMINO trials at the American Society of Retina Specialists meeting held in Stockholm, Sweden.
ASRS 2024: Topics attendees are keeping an eye on
July 17th 2024Sydney M. Crago, Assistant Managing Editor of Ophthalmology Times and Modern Retina, spoke with attendees, who shared which topics they are most looking forward to discussing at the American Society of Retina Specialists (ASRS) meeting held in Stockholm, Sweden.
ASRS 2024: Differential artery-vein analysis in eyes with diabetic retinopathy
July 17th 2024Jennifer Lim, MD, FARVO, FASRS, sat down with Sydney Crago, Assistant Managing Editor of Modern Retina, to discuss her presentation on differential artery-vein analysis in eyes with diabetic retinopathy and improvements on the OCTA classification using artificial intelligence at the American Society of Retina Specialists meeting held in Stockholm, Sweden.